The therapy is intended to restore hearing and support early speech development in children with OTOF-related congenital deafness.
Abigail Lewis
Advertisement
Articles by Abigail Lewis
The vice president of neuroscience at Voyager Therapeutics shared preclinical data on the company’s AAV-delivered RNA interference therapy, VY-1706.
The senior director at Regeneron discussed the company’s receptor-driven approach to AAV targeting, leveraging antibody engineering to enhance tissue specificity and reduce off-target effects.
Ocugen initiates pivotal confirmatory trial for OCU410ST, its second modifier gene therapy candidate, in patients with Stargardt disease.
Atsena Therapeutics will advance ATSN-201 into a pivotal phase 1/2/3 trial following FDA agreement on study design and endpoints.
Advertisement
Latest Updated Articles
First Patient Dosed in Phase 2/3 GARDian3 Trial of OCU410ST for Stargardt DiseasePublished: July 24th 2025 | Updated:
Rajeev Sivasankaran, PhD, on Voyager’s Single-Dose AAV Strategy for Silencing Tau for Alzheimer DiseasePublished: August 6th 2025 | Updated: August 6th 2025
Sven Moller-Tank, PhD, on Regeneron’s Precision Approach to AAV TargetingPublished: July 25th 2025 | Updated:
Advertisement
Advertisement
Trending on CGTlive®
1
FDA Activity Recap: November 2025 Features SMA Approval, Boxed Warning for Elevidys, and More
2
Around the Helix: Cell and Gene Therapy Company Updates – December 3, 2025
3
ImmunoLogic, Episode 7: "Turbocharging CAR T-Cells: The IL-9 Orthogonal Signal" With Anusha Kalbasi, MD
4
Key Unknowns Remain in Cell and Gene Therapy
5
